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Abstract
Purpose: To estimate the pooled prevalence and incidence of diabetic retinopathy (DR) in Iran and to
investigate their correlations with the Human Development Index (HDI), healthcare access (i.e., density of
specialists and sub-specialists), and methodological issues.
Methods: Electronic databases such as PubMed, Embase, Scopus, Web of Science, Google Scholar, and
local databases were searched for cohort and cross-sectional studies published prior to January 2018.
Prevalence and incidence rates of DR were extracted from January 2000 to December 2017 and random
effects models were used to estimate pooled effect sizes. The Joanna Briggs Institute critical appraisal tool
was applied for quality assessment of eligible studies.
Results: A total of 55,445 participants across 33 studies were included. The pooled prevalence (95% CI) of
DR in diabetic clinics (22 studies), eye clinics (4 studies), and general population (7 studies) was 31.8% (24.5
to 39.2), 57.8% (50.2 to 65.3), and 29.6% (22.6 to 36.5), respectively. It was 7.4% (3.9 to 10.8) for proliferative
DR and 7.1% (4.9 to 9.4) for clinically significant macular edema. The heterogeneity of individual estimates
of prevalence was highly significant. HDI (𝑃 < 0.001), density of specialists (𝑃 = 0.004), subspecialists (𝑃 <
0.001), and sampling site (𝑃 = 0.041) were associated with heterogeneity after the adjustment for type of DR,
duration of diabetes, study year, and proportion of diabetics with controlled HbA1C.
Conclusion: Human development and healthcare access were correlated with the prevalence of DR. Data
were scarce on the prevalence of DR in less developed provinces. Participant recruitment in eye clinics
might overestimate the prevalence of DR.
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INTRODUCTION
Diabetic retinopathy (DR) is the leading cause of
vision loss in adults aged 20-74 years, and remains
one of the foremost causes of blindness and
visual impairment worldwide.[1–4] Despite signifi-
cant development in the prevention and control of
DR, the proportion of DR increased by 7.7% among
all declining causes of blindness between 1990 and
2015.[5] The prevalence of DR strongly correlates
with both the duration of diabetes and the level
of glycemic control.[6] Therefore, timely manage-
ment of DR stemming from screening programs,
appropriate referral for treatment, and improving
healthcare accessibility are important in preserving
vision in diabetics.[7]
Although the treatment of DR can decrease the
risk of visual loss by 60%, it imposes a heavy
cost to the healthcare system.[8] Despite some
improvements in diagnostic assessment and treat-
ment options,[6] the lack of qualified healthcare
services along with a Westernized lifestyle have
caused the burden of DR to be high and on the
rise in developing countries.[7, 8] DR is a pressing
public health matter, probably due to suboptimal
access to diabetes care services such as eye care
professionals and eye care services, especially
in low- to middle-income countries.[8] Low human
development might be another correlate of the
increasing burden of DR. To the best of our knowl-
edge, no study has investigated the correlation
between human development and DR. The only
study on this subject assessed the association
between the Human Development Index (HDI) and
the number of studies published on DR.[9] HDI
is abstracted from income, education, and life
expectancy markers and ranks areas into different
levels of human development.[10]
Despite the high prevalence of diabetes, there
are few reliable national studies on the incidence,
prevalence, and correlates of DR in developing
countries.[11] Of note, Iran is a country in transi-
tion, having a high variety of healthcare access
options and human development as well as a
huge variation in the prevalence and incidence of
DR across its geographic regions.[12–14] Therefore,
besides assessing the prevalence and incidence
of DR, their adjusted correlations with HDI and




The Meta-analysis of Observational Studies in Epi-
demiology (MOOSE) guidelines were followed.[15]
The study protocol was approved by the Shiraz
University of Medical Sciences (ethical approval
code: IR.SUMS.MED.REC.1397.256).
Eligibility Criteria
Observational studies (prospective or retrospective
cohort and cross-sectional) were included if they
provided sufficient information about the incidence
and prevalence of DR and clinically significant
macular edema (CSME). No restriction was applied
on the year of publication or type of diabetes, and
all studies published in Persian or English language
were included. These two languages covered all
studies published about the Iranian population and
we did not find studies in other languages.
Search Strategy
We performed a systematic search for the preva-
lence and incidence of DR, summarized in Figure 1.
PubMed, Scopus, Web of Science, Google Scholar,
Embase, and the local databases of SID and Iran
Doc were searched for articles published between
January 2000 and December 2017. Our search was
limited to studies related to Iran. The search terms
included: “diabetes” or “diabetic” combined with
”complication” or “retina” or “vision” or “visual” or
“retinopathy” or “blindness” or “clinically significant
macular edema” and “Iran” and “Epidemiology” or
“incidence” or “prevalence” or “proportion”. Review
articles and their references were checked for
additional studies. The gray literature evaluation
was performed using international and regional
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congresses that were held during the study period
around the world and specifically in Iran, and we
selected and hand searched the abstract books
that were obtainable as much as possible. We also
searched university websites for thesis and reports
that were related to the subject during the study
period. References of all included studieswere also
searched for potentially eligible studies. In cases
where the full text of an article was unavailable, the
corresponding author was contacted. Documents
were catalogued using Endnote X4.
Study Selection
In case of repeated publications from one study,
the newest publication was included. Titles,
abstracts, and the full texts of retrieved articles
were reviewed independently by two experts
in the field and eligible articles were selected.
Studies on children, pregnant women, or non-
Iranian populations were excluded as well as
experimental studies, secondary studies, letters,
case-reports, case-series, commentaries, and
editorials. Clinical trials were also excluded.
Studies with a non-representative sample or
irrelevant comorbidities were also excluded. Also,
in the case of disagreement regarding exclusion
or inclusion of a study, a consensus was reached
through discussion between the authors.
Data Extraction and Risk of Bias Assessment
We performed a comprehensive literature review
and designed a conceptual framework. An excel
(MS Office) data sheet based on clinical principles
was prepared for data extraction using our frame-
work. The following variables were included in the
data extraction form: first author, publication year,
study year, study location (i.e., province/district),
urbanization ratio (number of participants from the
urban area/number of participants from the rural
area; based on the data presented in each individ-
ual study), sampling site (diabetes clinic, eye clinic,
or general population), sampling design (random,
multistage, convenient, unknown), study design
(cross-sectional, cohort), sample size (overall and
for subgroups), age range (or mean age), duration
of study, gender (or female/male ratio), diagnos-
tic methods of DR,[16] proportion of diabetics (in
population-based studies), type of diabetes (or type
I/type II ratio), type of DR (i.e., non-proliferative dia-
betic retinopathy [NPDR]) and its stage (mild, mod-
erate, or severe), proliferative diabetic retinopathy
(PDR), CSME, mean HbA1C (overall, among DR
patients, and among non-DR patients), number
of DR patients (or estimated prevalence and its
standard error), number of incident cases of DR
(or cumulative incidence rate; only for cohort
studies), number of person-years of follow-up (in
cohort studies), duration of DM (overall, among
DR patients, and among non-DR patients), mean
age at the onset of DM, mean duration of DR,
and proportion of patients with newly diagnosed
DM. The aforementioned data were extracted (if
available) and 25% of the extracted data were
randomly cross-checked by another author. Also,
in the case of disagreement regarding data extrac-
tion, a consensus was reached through discussion
between the authors. Since several studies had
not reported exact values for some variables, more
than 30 disagreements on the most appropriate
estimates for these missing values were discussed
in the team.
The Joanna Briggs Institute ( JBI)’s critical
appraisal tool[17] was applied for quality assessment
of eligible studies. Quality assessments and critical
appraisals were performed by two different authors
independently. In the case of disagreement
regarding the quality score, a consensus was
reached through discussion between the authors
(4 studies out of the included 33 studies).
Data on Human Development and
Healthcare Access
The density of specialists and subspecialists (num-
bers of specialists and subspecialists in the health-
care systemof each province to the total population
in that province) was retrieved from a recent reliable
report by Haghdoost et al[18] as indices of health-
care access. Density ratios were categorized into
quantiles. Haghdoost et al gathered the number
of physicians based on the questionnaires filled
out by medical universities all around Iran. Their
study was a part of a project to define the national
treatment map of Iran in 2025 (Naghsh-e Rahe
Darman-e Iran). In order to control the precision of
completing the questionnaire, their data was cross-
checked with the Medical Registry Information Sys-
tem and different medical insurance companies.[18]
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Figure 1. Flow diagram summarizing the systematic search and review process for identifying evidence regarding the prevalence
and diabetic retinopathy. Inclusion and exclusion criteria are provided in the text.
HDI indices (less developed, moderately devel-
oped, and developed) were retrieved for each
province according to the study performed by
Safaeipour et al[12] and used as an independent
variable in meta-regression modeling.
Data Preparation and Statistical Analysis
Point estimates of prevalence were extracted or
calculated as the number of patients with DR
divided by the number of patients with DM. Addi-
tionally, prevalence estimates of DR in the popula-
tion, regardless of diabetic status, were estimated
as the number of participants with DR divided
by the number of total participants in population-
based studies. A 95% confidence interval (CI) for all
individual point estimates of prevalence was esti-
mated where it was not mentioned.[19] Cumulative
incidence proportions (per 100 person-years) were
calculated as the number of new DR cases divided
by the number of at-risk person-years (i.e., number
of study subjects multiplied by number of follow-up
years).
To ensure the independence of point estimates
in primary studies as well as to prevent repeated
counting of participants in primary studies, only one
of the overall or subgroup point estimates of each
primary study was included in the meta-analysis
and meta-regression models. The heterogeneity of
individual estimates of prevalence was assessed
according to the I-square statistic above 50%.[20]
In cases of high heterogeneity, correlates were
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conceptualized. Then, the significance and magni-
tude of their correlationwere investigated using the
random-effects meta-regression technique.
Subgroup analyses were performed according
to the most important correlates of heterogeneity
if applicable (i.e., sampling site, geographical loca-
tion, HDI and healthcare access). Due to persistent
heterogeneity (even after subgroup analysis), indi-
vidual estimates of prevalence and incidence were
pooled using the DerSimonian and Laird random-
effects modeling method. Publication bias was
investigated using Begg’s and Egger’s tests. Data
analysis and calculations were performed using
Stata software, version 11.2 (Stata Corporation,
College Station, TX, USA). A two-sided 𝑃 < 0.05
was considered as statistically significant. We also
provided appropriate tables and graphs for show-
ing our results (i.e., included studies, shortage in
studies, methods applied for the diagnosis of DR by
primary studies, study flowchart, and study forest
plot by HDI categories). The study protocol was
registered in the International Prospective Register
of Systematic Reviews (PROSPERO), under the
registration number CRD42018104626.
RESULTS
The initial search resulted in 2,153 records. Of
these, 426 records were included in the full-
text review process, and finally, 33 studies were
included in the meta-analysis.
Overview of Included Studies
Thirty cross-sectional and three cohort studies
were included in the analysis, representing an
overall number of 55,445 diabetic patients includ-
ing 17,155 patients with DR [Table 1]. Among
cross-sectional studies, seven had a population-
based sampling design representing 24,623 par-
ticipants including 5,657 diabetic patients and
2,049 patients with DR. Included cohort studies
represented 1,174 diabetic patients (equivalent to
5,400 person-years) and 613 incident cases of DR.
Assessment of Heterogeneity in
Individual Estimates for Prevalence of
Diabetic Retinopathy
In cross-sectional studies conducted in diabetes
clinics, individual estimates for the prevalence of
DR were significantly heterogeneous for overall
diabetics (I-square, 99.5; 𝑃 < 0.001; the hetero-
geneity was similar between genders [I-square,
99.4; 𝑃 < 0.001]). Also, individual estimates for the
prevalence of DR were highly heterogeneous in
studies conducted in eye clinics (I-square, 98.0;
𝑃 < 0.001) and population-based studies (I-square,
95.7; 𝑃 < 0.001). Additionally, in three cohort
studies, the estimates of individual cumulative
incidence of DR were statistically heterogeneous
with a highly significant I-square of 97.9 (𝑃 < 0.001).
Determinants of DR Prevalence (Correlates of
Heterogeneity of Individual Estimates)
According to the random-effects meta-regression
model, HDI (as an ordinal variable of tertile of
HDI; adjusted OR: 0.12, 95% CI: 0.05 to 0.34,
𝑃 < 0.001), density of specialists (as an ordinal
variable including quintile of density ratio; adjusted
OR: 1.13, 95% CI: 1.04 to 1.23, 𝑃 = 0.004), density
of subspecialists (as an ordinal variable including
quintile of density ratio; adjusted OR: 0.85, 95%
CI: 0.78 to 0.91, 𝑃 < 0.001), type of DR (reference
is PDR; adjusted OR: 1.30, 95% CI: 1.10 to 1.42, 𝑃
< 0.001), duration of diabetes (adjusted OR: 1.05,
95% CI: 1.04 to 1.07, 𝑃 < 0.001), site of study
sampling (reference is population-based sampling;
adjusted OR: 1.09, 95% CI: 1.02 to 1.17, 𝑃 = 0.041),
study year (adjusted OR: 0.97, 95% CI: 0.96 to
0.98, 𝑃 < 0.001), and proportion of diabetics with
controlled HbA1C (adjusted OR: 0.92, 95% CI: 0.87
to 0.97, 𝑃 = 0.005) were significantly associated
with the heterogeneity of individual estimates of DR
prevalence.
Risk of bias was not associated with heterogene-
ity (𝑃 = 0.683). Type of diabetes was not a sig-
nificant determinant of heterogeneity for individual
estimates of DR prevalence (𝑃 = 0.10).
Due to the lack of enough data to achieve
individual estimates of cumulative incidence, meta-
regression modeling for cumulative incidence was
not applicable.
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Prevalence of DR among Diabetic Patients
Due to high heterogeneity, pooled prevalence
estimates might have some extent of bias from an
epidemiological point of view. The range for overall
prevalence of DR among diabetics was 9.0- 63.4%.
(The pooled estimate of prevalence using random-
effect model was 33.6% [95% CI: 27.9, 39.2], 40.6%
[95% CI: 28.9, 52.3], and 35.7% [95% CI: 26.0, 39.4]
overall in males and females, respectively [Figure
2]).
The pooled prevalence of NPDR, mild NPDR,
moderate NPDR, and severe NPDR among diabetic
patients were 24.8% (95% CI: 18.7, 30.9), 14.1% (95%
CI: 9.1, 19.2), 8.9% (95% CI: 4.7, 13.0), and 3.3% (95%
CI: 2.0, 4.6), respectively. The pooled prevalence
of PDR and CSME were 7.4% (95% CI: 3.9, 10.8) and
7.1% (95% CI: 4.9, 9.4), respectively.
Due to significant heterogeneity among studies,
the analysis was performed through subgroup
analysis based on the most important correlates of
heterogeneity.
Prevalence of DR among Patients Referred to
Diabetic Clinics
The overall pooled prevalence rate of DR among
diabetic patients was 31.8% (95%CI: 24.5, 39.2) and
39.1% (95% CI: 23.5, 54.6) among male subjects
and 34.6% (95% CI: 23.2, 45.9) among female
subjects.
The pooled prevalence rates of NPDR, mild
NPDR, moderate NPDR, and severe NPDR among
diabetic patients were 21.0% (95% CI: 12.7, 29.3),
11.1% (95% CI: 3.3, 18.9), 5.6% (95% CI: 0.7, 11.9), and
2.2% (95% CI: 1.2, 3.3), respectively. The pooled
prevalence rates of PDR and CSME among diabetic
patients were 2.9% (95% CI: 1.3, 4.5) and 7.4% (95%
CI: 6.1, 8.6).
The pooled estimate of prevalence of DR based
on studies including only type II diabetics was
33.3% (95% CI: 24.4, 42.2), whereas, it was 22.6%
(95% CI: 12.8, 32.3) in those with both types of
diabetes.
The pooled prevalence rates of DR in the central,
northeast, northwest, southeast, and southwest
geographic regions of Iran were 42.9% (95% CI:
30.4, 55.3), 51.4% (95% CI: 45.2, 57.5), 26.6% (95%
CI: 18.6, 34.6), 45.1% (95% CI: 40.3, 49.9), and 10.4%
(95% CI: 8.7, 12.5), respectively, and 30.8% (95% CI:
26.6, 35.0) for Tehran (the capital city of Iran).
Prevalence of DR among Patients Referred to
Eye Clinics
The overall pooled prevalence of DR among dia-
betic patients was 57.8% (95% CI: 50.2, 65.3) and
63.0% (95% CI: 60.4, 65.6) among males and
61.3% (95% CI: 57.0, 65.7) among females. The
pooled prevalence rates of NPDR and PDR were
29.0% (95% CI: 23.4, 34.5) and 19.4% (95 % CI:
14.6, 24.3), respectively. The pooled estimate of
DR prevalence was 48.8% (95% CI: 42.7, 55.0) in
studies including only type II diabetics and 64.6%
(95% CI: 62.2, 67.0) in studies including both types
of diabetes. The pooled prevalence rates of DR in
the north and southwest geographical regions of
Iran were 58.4% (95% CI: 51.3, 65.5) and 48.8%
(95% CI: 44.5, 53.2), respectively, and 39.1% (95%
CI: 27.2, 51.0) in Tehran.
Prevalence of DR among Patients in
Population-based Studies
The overall pooled prevalence of DR was 29.6%
(95% CI: 22.6, 36.5) and 36.8% (95% CI: 30.5,
43.2) among male subjects and 29.0% (95% CI:
24.6, 33.6) among female subjects. The pooled
prevalence rates of DR in the central, north, and
northwest geographical regions of Iran were 29.9%
(95% CI: 26.4, 33.4), 24.4% (95% CI: 21.3, 27.5), and
32.5% (95% CI: 27.7, 37.4), respectively, and 32.8%
(95% CI: 22.3, 43.3) in Tehran.
Prevalence of DR in the General Population
The overall pooled prevalence of DR (according to
the population-based studies) was 3.6% (95% CI:
2.4, 5.0) and 3.5% (95% CI: 1.5, 6.4) among male
subjects and 3.6% (95% CI: 2.1, 5.6) among female
subjects.
Cumulative Incidence Rate of DR in Diabetics
The overall pooled cumulative incidence rate (per
100 person-years) of DR was 11.7% (95% CI: 8.0,
15.9) and 9.6% (95% CI: 7.8, 11.8) among male
subjects and 8.7% (95% CI: 7.5, 10.0) among female
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Figure 2. Forest plot of diabetic retinopathy prevalence by Human Development Index categories and source of data (clinic vs
population-based studies). CI, confidence interval; ES, estimation of diabetic retinopathy prevalence (%); HDI, HumanDevelopment
Index.
subjects [Figure 3]. The pooled cumulative inci-
dence rates (per 100 person-years) for NPDR and
PDR were 11.7% (95% CI: 9.1, 14.9) and 0.2% (95 %
CI: 0.0, 1.1), respectively.
More Details on the Association of HDI and
the Prevalence of DR
The estimation of linear correlation coefficient
between HDI and the prevalence of DR among
diabetics was -0.18 with a 𝑃 of 0.029 (a relatively
low but significant linear correlation) [Figure 4].
Reporting and Methodological Shortcomings
One study used the survey data analysis technique
to consider multistage sampling design.[50] Two
studies reported age-adjusted estimates.[30, 40]
Only 33.3% (n = 11) of the studies reported their DR
results by gender [Table 2].
Assessment of DR
According to the current results, 54.54% (n = 18)
of studies performed indirect ophthalmoscopy with
pupillary dilatation for the evaluation of DR. Others
probably used the same method; however, this
matter was not clearly stated [Table 3].
Publication Bias
There was no significant publication bias (Begg’s
test 𝑃 = 0.824; Egger’s test 𝑃 = 0.075) in the current
study.
DISCUSSION
In the current study, the pooled prevalence and
incidence of DR including PDR and NPDR among
Iranian diabetic subjects referred to diabetes clinics
and eye clinics and the pooled prevalence of
DR among diabetics retrieved form population-
based studies were determined based on the
English language studies only. Persian articles
were excluded due to poor quality score in our
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Figure 3. Forest plot of cumulative incidence rate of diabetic retinopathy. CI, confidence interval; ES, estimation of diabetic
retinopathy incidence (%)
Figure 4. Scatter plot of the linear correlation of prevalence and the Human Development Index. DR, diabetic retinopathy
assessment. We found no publication bias among
the included studies. The human development,
access to subspecialists and specialists, and site
of study sampling had a correlation with the preva-
lence of DR among diabetics.
Studies from other parts of the world reflect
significant differences in the prevalence of DR
depending on the factors such as ethnicity, demog-
raphy, and access to healthcare systems.[51, 52]
According to the current results, an increase in
HDI was independently correlated with lower DR
prevalence. In order to avoid the bias of ecological
inference fallacy, this finding could only be inter-
preted from an ecological point of view. Therefore,
we cannot directly relate the DR prevalence in
individuals to the HDI in each province. However,
HDI may potentially be a good index of quality
of diabetes care in developing countries such as
Iran at a national level. This finding is consistent
with previous evidence from low-income regions
of developed countries.[53] The prevalence of DR
and PDR/NPDR ratio were higher in eye clinics in
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Table 2. Number (%) of studies reporting important criteria required in epidemiological studies on diabetic retinopathy
Reportable variables Studies on subjects with DM
N (%)
Studies on subjects with DR
N (%)
Study year 26 (78.7) 26 (78.7)
Source of recruitment 33 (100) 33 (100)
Sample size 33 (100) 30 (90)
Gender 33 (100) 11 (33.3)
Age (Mean ± SD) 22 (66.6) 16 (48.4)
Dividing sample of study by age groups 1 (3.0) 1 (3.0)
Type of DM 27 (81.8) 27 (81.8)
Proportion of DM types (n = 11)* 2(18.2) 0
Duration of DM 14 (42.4) 11 (33.3)
Proportion of patients with controlled DM 1(3.0) 0
Type of retinopathy 14 (42.4) 14 (42.4)
Mean age at diagnosis of Diabetes 3.0 (9.0) 3.0 (9.0)
HbA1c (Mean ± SD) 20 (60.6) 15 (45)
Age-Gender adjusted prevalence of retinopathy 2 (6) 2 (6)
*Only 11 studies included both types of DM. The others reported one type of the DM in their sample size. Proportion of
the DM types in these 11 studies is considered to be an important factor for both diabetics and patients with DR.
DM, diabetes mellitus; DR, diabetic retinopathy; HbA1c, hemoglobin A1c; N, number; SD, standard deviation
Table 3. Findings about diagnostic methods for diabetic retinopathy
Diagnostic method Number of studies Percent
Indirect ophthalmoscopy 11 33.33
Indirect ophthalmoscopy and fluorescein angiography 3 9.09
Indirect ophthalmoscopy and fundus photography 4 12.12
Questionnaires/Records 7 21.21
Fundoscopic and angiographic findings 1 3.03
Slit-Lamp biomicroscopy of the posterior pole using contact lens 1 3.03
Eye examination and fundus photography 1 3.03
Ophthalmic examination (not mentioned exactly) 5 15.15
Total number of studies 33 100
comparison to the DM clinics. It might be due to
the higher detection rate of DR, especially PDR in
eye clinics.[54–56] In other words, more advanced
patients are usually referred to the eye clinics.
The density of subspecialists was negatively
correlated with the prevalence of DR. This could
be due to health literacy, greater access to health-
care services in regions where subspecialists
work, leading to more effective diabetes con-
trol. This finding is in accordance with previous
reports.[51, 52, 57] Of note, many confounding factors
such as social factors could be associated with the
density of subspecialists and prevalence of DR. It
might also be due to the interest of subspecialists
to be in areas with higher socioeconomic status in
which inhabitants may also have a better access to
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healthy food, causing more controlled DM and less
prevalence of DR.
The pooled population-based prevalence of DR
among diabetics was close to the maximum esti-
mates of DR prevalence reported in developing
countries such as Pakistan (29% vs 25- 29%),
while it was lower than the prevalence reported
in developed countries.[58–62] Population aging and
Westernized lifestyle could have been among the
factors increasing the prevalence of diabetes and
DR in Iran and other developing countries.[11, 58, 63]
In addition, the higher prevalence of DR among
male subjects could be attributed to lifestyle habits
such as cigarette smoking, which is consistent with
studies conducted in India and Nepal.[58, 59]
The pooled prevalence of DR among diabetics
referred to eye clinics was significantly higher
than that in diabetes clinics. Routine screening by
an ophthalmologist is not a common practice in
developing countries.[64] Thus, this higher preva-
lence may be due to higher rates of referral for
patients presenting with visual symptoms. There
is a need for improving screening programs in
primary healthcare services and communication
between primary healthcare providers and oph-
thalmologists to ensure diabetics receive timely
ophthalmic examinations.
Based on the results of the current study, the
estimation of DR prevalence among diabetics in
eye clinics may not be a good indicator of DR
prevalence among diabetics; however, a compar-
ison of DR prevalence in diabetic and eye clinics
could help determine the sensitivity and specificity
of referrals to eye clinics by clinicians and over-
/underutilization of eye care in developing coun-
tries.
Although, overall and gender-specific pooled
prevalence rates of DR among diabetics referred to
diabetes clinics were relatively higher than those in
population-based studies, these differences were
not meaningful. In addition, the female/male ratio of
estimated DR prevalence in DM clinics studies was
almost equal to the population-based studies (88%
vs 80%). Therefore, considering the difficulties in
conducting robust population-based studies, it is
reasonable to estimate the prevalence of DR in
diabetes clinics, especially in developing counties
such as Iran.
The pooled estimate of DR incidence among
diabetics in Iran was less than recent reports
from developed countries such as Canada, the
UK, and Spain.[61, 65, 66] Moreover, the estimated
incidence was relatively higher than India, South
Korea, andDenmark.[67–69] According to the current
study, the available data on the incidence of DR in
Iran is inadequate; further studies are needed to
determine the incidence of DR in Iran.
Among the eligible studies included in the
current meta-analysis, only one study reported
the prevalence of DR among Type I diabetics.[27]
Accordingly, the pooled estimates provided in the
current study are mostly representative of the
prevalence of DR among Type II diabetics. More
studies on the incidence and prevalence of DR
among Type I diabetics are needed.
The results of this study showed that there is a
lack of research on the prevalence of DR in less
developed provinces, such as Sistan and Balochis-
tan, Bushehr, Hormozgan, Khorasan, Khozestan,
Kermanshah, Kordistan, Kohkiloieye, Chaharmahal
and Bakhtiyari, and Lorestan. Missing data from
these provinces could have affected the results
of the current study. In addition to the paucity
of data in some provinces, there is a significant
heterogeneity among studies, which means that
making an accurate single prevalence estimate of
DR is not possible. The pooled prevalence of DR
was 29%. However, the prevalence rate varied
from 9% to 64.1%. Thus, it might not be completely
representative of the actual DR prevalence.
In addition to the aforementioned factors, the
method used for detecting DR is a major fac-
tor that can influence prevalence estimates. It is
crucial to know which specific diagnostic method
(i.e., dilated fundus examination, direct or indirect
ophthalmoscopy, digital imaging, etc.) was used in
each study.[70] The ophthalmic examination meth-
ods were not adequately explained in at least 12
included studies. In the course of DR, patients
might develop maculopathy with no significant
change in vision and may not seek medical care.
Optical coherence tomography (OCT) is an impor-
tant test in the evaluation and management of
diabetic macular edema and can detect subclinical
macular edema.MissingOCT evaluation could lead
to many diabetics remaining undiagnosed in the
early stage of DR.[71]
The current study has some limitations. The
pooling of data from different sources introduced
potential sources of heterogeneity that could
impact accuracy. Various studies could have dif-
ferent inclusion criteria, sample selection, or study
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protocols. For example, the sample from a diabetes
clinic differs from an eye clinic or population-based
studies. The pooled estimate of DR prevalence
by gender in the current study was sometimes
not compatible with the total prevalence in the
subgroups, which was due to the lack of reporting
DR by gender in some studies. Studies in which
the diagnosis of DM was based on patient self-
report, without lab test confirmation, could have
led to an overestimation of DR prevalence due
to the exclusion of undiagnosed diabetes from
the study sample. Although it is desirable to have
the HDI and density of specialists and subspe-
cialists at the time of each study to calculate the
correlations and perform the analyses, only two
up-to-date and available studies were used for
estimating the value of both mentioned variables.
Also, the absence of studies from the eastern,
western, and southern regions of Iran could have
also affected the validity and generalizability of
the current findings. Although our findings on
the prevalence and incidence of DR may not be
generalizable to all countries, it could be useful
for developing countries, especially regions with
similar socioeconomic, demographic, cultural, and
geographic conditions.
SUMMARY
Despite the scarcity of research in less developed
regions, a reasonable estimate for the prevalence
of DR among Iranian diabetic subjects is around
30% (29% among female and 37% among male
subjects). HDI, density of specialists and sub-
specialists, and sampling site were independently
correlated with the prevalence of DR in Iran. The
most reliable evidence on DR prevalence is likely
to be retrieved from diabetes clinics in developing
countries. Furthermore, providing a list of essential
items for reporting the descriptive epidemiology
of DR and performing studies in less developed
regions could generate stronger evidence for
health policy programs.
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